NCT04423367View on ClinicalTrials.gov

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 13, 2020

Primary Completion Date

July 31, 2024

Study Completion Date

September 30, 2024

Conditions

Acquired Pure Red Cell Aplasia

Interventions

DRUG

bortezomib/dexamethasone

Enrolled patients would receive the combination therapy of bortezomib and dexamethasone.

Trial Locations (3)

Unknown

Zhoukou Central Hospital, Zhoukou

The Second Affilated Hospital of Shandong First Medical University, Tai’an

Regenerative Medicine Center, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT04423367 - Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment | Biotech Hunter | Biotech Hunter